人民财讯12月30日电，洁特生物(688026)12月30日公告，拟以1500万元—3000万元回购股份，用于员工 持股计划或股权激励，回购价格不超过25.32元/股。回购资金来源为公司自有资金。 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-072 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于以集中竞价交易方式回购股份方案的公告 暨回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关股东是否存在减持计划：截至本公告日，公司的董事、高级管理人员、控 股股东、实际控制人及一致行动人、持股 5%以上的股东在未来 3 个月、未来 6 个 月内暂未明确是否存在减持公司股份的计划。若上述相关方在回购期间拟实施减 持公司股份计划，公司将严格按照有关法律、法规及规范性文件的相关规定及时 履行信息披露义务。 ● 相关风险提示： 1、本次回购可能存在回购期限内公司股票价格持续超出回购价格上限，进而 导致本次回购方案无法顺利实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素影响， 致使本次回购股份所需资金未能筹措到位，可能存在回购方案无法实施或者部分 实施 ...

Core Viewpoint - The company has announced a postponement of the project "Research and Development of New Biological Laboratory Consumables" from December 2025 to December 2026 due to longer-than-expected construction cycles for automated production lines and new cleanroom facilities [1] Group 1: Project Details - The total investment for the project is 40.1423 million yuan, with 40 million yuan sourced from funds raised through the issuance of convertible bonds in 2022 [1] - The funds will primarily be used for the research and development of new biological laboratory consumables [1] Group 2: Reasons for Delay - The delay is attributed to the lengthy construction periods for the automated production line and new factory and cleanroom facilities, which have impacted the R&D progress [1] - The company has made a cautious decision to postpone the project to ensure the quality of research and maintain international competitiveness [1] Group 3: Impact of Delay - The postponement does not change the project implementation entity, total investment, or intended use of funds, and will not materially affect the implementation of the fundraising project [1] - There are no indications of a disguised change in the direction of raised funds or harm to shareholder interests, and the delay is not expected to have a significant adverse impact on the company's normal operations [1] - The decision aligns with the company's long-term development plan [1]

Group 1 - The company plans to acquire a 70% stake in Guangdong Jieke Membrane Separation Technology Co., Ltd. for a total consideration of RMB 7.9199 million [1] - Upon completion of the transaction, the company will directly hold 70% of Jieke Membrane, which will become a subsidiary and be included in the company's consolidated financial statements [1] - The transaction involves related parties, including the company's controlling shareholder Yuan Jianhua and his concerted actors, but it does not constitute a major asset restructuring as defined by the regulations [1]

Group 1 - A new company named Zhong Sai Bai Tai Biotechnology (Hangzhou) Co., Ltd. has been established, focusing on artificial intelligence application software development [1] - The company's business scope also includes general mechanical equipment installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biological (688026) and other stakeholders [1]

Core Viewpoint - Recently, Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. was established, focusing on artificial intelligence application software development and other related services [1] Company Summary - Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. has a business scope that includes artificial intelligence application software development, general machinery installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biotechnology and other stakeholders [1]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock price performance [6][11]. Group 1: Board Meeting Decisions - The fourth board meeting of the company was held on November 21, 2025, with all seven directors present, and the decision was made to not adjust the conversion price of the "Jiet Bio" convertible bonds [1][2]. - The decision was made with a vote of 4 in favor, 0 against, and 0 abstentions [2]. Group 2: Convertible Bond Details - The "Jiet Bio" convertible bonds were issued in 2022, with a total of 4.4 million bonds at a face value of 100 RMB each, raising a total of 440 million RMB [8]. - The initial conversion price was set at 48.23 RMB per share, which has been adjusted multiple times due to various corporate actions [9]. Group 3: Price Adjustment Clause - The downward adjustment clause for the conversion price is triggered when the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - As of the announcement date, the stock price had indeed triggered this clause, but the board decided against making any adjustments for the next three months [11].

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 25th meeting of the fourth board of directors on November 21, 2025, via telecommunication, where it reviewed the proposal regarding not adjusting the conversion price of "Jiet Convertible Bonds" [1] - For the year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other businesses account for 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.4 billion yuan [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-068 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于不向下修正"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、转股价格调整/修正依据 （一）"洁特转债"基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生物过滤股份有限公司（以下简称"公司"）向不特定对象共计发 行 440.00 万张，每张面值为人民币 100 元，按面值发行。本次发行合计募集资 金人民币 44,000.00 万元。经上海证券交易所《自律监管决定书》（[2022]203 号 文）同意，公司 44,000.00 万元可转换公司债券已于 2022 年 8 月 2 日起在上海证 券交易所挂牌交易，债券简称"洁特转债"，债券代码"11 ...

一、审议通过《关于不向下修正"洁特转债"转股价格的议案》 具体内容详见公司同日刊载于《中国证券报》《证券时报》《上海证券报》 《证券日报》及上海证券交易所（www.sse.com.cn）的《关于不向下修正"洁特 转债"转股价格的公告》（公告编号：2025-068）。 表决结果：4 票同意，0 票反对，0 票弃权。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-067 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十五次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议于 2025 年 11 月 21 日以通讯的方式召开，会议通知已于 2025 年 11 月 14 日通过电子邮件的方式送达全体董事。本次会议应出席董事 7 人，实际出席 董事 7 人。会议由董事长袁建华主持，会议召开符合有关法律、法规、规章和 ...